Phenotypic Variability of an Inherited Pathogenic Variant in CIC Gene: A New Case Report in Two-Generation Family and Literature Review

Abstract

CIC encodes capicua protein, a transcriptional repressor that is highly expressed in developing brains. A previous study reported pathogenic mutations in the CIC gene in five individuals with significant neurodevelopmental disorders of intellectual disability, epilepsy, and autism spectrum disorder. All these mutations are either de novo or likely due to germline mosaicism. Here we reported a pathogenic mutation (c.2694dupC; p.K899Qfs X32: NM_015125) in the CIC gene in three members of a two-generation family presenting with neurodevelopmental impairment but has significant phenotypic variability. Interestingly, loss of function variants of somatic origin are frequently found in cancers of brain and other organs. We summarized germline and somatic pathogenic or loss of function variants in CIC gene in public genome databases through in silico analysis and published literature. Our findings provided further evidence to support the review of haploinsufficiency of CIC in neurodevelopmental disorder, in addition to suggesting a strong modifier effect for the CIC mutations.

Keywords

CIC - capicua - absence seizure - autism spectrum disorder

^∗ Current Contact: Department of Genetics, Yale University School of Medicine, Office: WWW 313 PO Box 208005, United States.

Note

Informed consent was obtained for this study and publication.

Publication History

Received: 01 April 2020

Accepted: 24 May 2020

Article published online:
20 August 2020

• References

• 1 Lee CJ, Chan WI, Cheung M. et al. CIC, a member of a novel subfamily of the HMG-box superfamily, is transiently expressed in developing granule neurons. Brain Res Mol Brain Res 2002; 106 (1-2): 151-156
• 2 Lee CJ, Chan WI, Scotting PJ. CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas. J Neurooncol 2005; 73 (02) 101-108
• 3 Lam YC, Bowman AB, Jafar-Nejad P. et al. ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 2006; 127 (07) 1335-1347
• 4 Lu HC, Tan Q, Rousseaux MW. et al. Disruption of the ATXN1-CIC complex causes a spectrum of neurobehavioral phenotypes in mice and humans. Nat Genet 2017; 49 (04) 527-536
• 5 Jiménez G, Guichet A, Ephrussi A, Casanova J. Relief of gene repression by torso RTK signaling: role of capicua in Drosophila terminal and dorsoventral patterning. Genes Dev 2000; 14 (02) 224-231
• 6 Yip S, Butterfield YS, Morozova O. et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012; 226 (01) 7-16
• 7 Wong D, Lounsbury K, Lum A. et al. Transcriptomic analysis of CIC and ATXN1L reveal a functional relationship exploited by cancer. Oncogene 2019; 38 (02) 273-290
• 8 Tanaka M, Yoshimoto T, Nakamura T. A double-edged sword: the world according to Capicua in cancer. Cancer Sci 2017; 108 (12) 2319-2325
• 9 Yang R, Chen LH, Hansen LJ. et al. Cic loss promotes gliomagenesis via aberrant neural stem cell proliferation and differentiation. Cancer Res 2017; 77 (22) 6097-6108
• 10 Bettegowda C, Agrawal N, Jiao Y. et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011; 333 (6048): 1453-1455
• 11 Vissers LE, de Ligt J, Gilissen C. et al. A de novo paradigm for mental retardation. Nat Genet 2010; 42 (12) 1109-1112
• 12 Tan Q, Zoghbi HY. Mouse models as a tool for discovering new neurological diseases. Neurobiol Learn Mem 2019; 165: 106902
• 13 Duffney LJ, Valdez P, Tremblay MW. et al. Epigenetics and autism spectrum disorder: a report of an autism case with mutation in H1 linker histone HIST1H1E and literature review. Am J Med Genet B Neuropsychiatr Genet 2018; 177 (04) 426-433
• 14 Lek M, Karczewski KJ, Minikel EV. et al; Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016; 536 (7616): 285-291
• 15 Sahm F, Koelsche C, Meyer J. et al. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 2012; 123 (06) 853-860
• 16 Da Via MC, Solimando AG, Garitano-Trojaola A. et al. CIC Mutation as a molecular mechanism of acquired resistance to combined BRAF-MEK inhibition in extramedullary multiple myeloma with central nervous system involvement. Oncologist 2019; 25 (02) 112-118
• 17 Okimoto RA, Breitenbuecher F, Olivas VR. et al. Inactivation of Capicua drives cancer metastasis. Nat Genet 2017; 49 (01) 87-96
• 18 Lee Y, Fryer JD, Kang H. et al. ATXN1 protein family and CIC regulate extracellular matrix remodeling and lung alveolarization. Dev Cell 2011; 21 (04) 746-757
• 19 Tan Q, Brunetti L, Rousseaux MWC. et al. Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma. Proc Natl Acad Sci U S A 2018; 115 (07) E1511-E1519
• 20 Rauen KA. The RASopathies. Annu Rev Genomics Hum Genet 2013; 14: 355-369
• 21 Bunda S, Heir P, Metcalf J. et al. CIC protein instability contributes to tumorigenesis in glioblastoma. Nat Commun 2019; 10 (01) 661
• 22 Weissmann S, Cloos PA, Sidoli S, Jensen ON, Pollard S, Helin K. The tumor suppressor CIC directly regulates MAPK pathway genes via histone deacetylation. Cancer Res 2018; 78 (15) 4114-4125
• 23 Simón-Carrasco L, Graña O, Salmón M. et al. Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma. Genes Dev 2017; 31 (14) 1456-1468
• 24 Qi H, Dong C, Chung WK, Wang K, Shen Y. Deep genetic connection between cancer and developmental disorders. Hum Mutat 2016; 37 (10) 1042-1050